Neutrophil inhibitory factor-hirulog hybridAlternative Names: rNIF-hirulog; TNHH
Latest Information Update: 28 May 2016
At a glance
- Originator Chongqing Fagen Biopharmaceutical
- Developer Chongqing Fagen Biopharmaceutical; West China Hospital Sichuan University
- Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action CD11b antigen modulators; CD18 antigen modulators; Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Stroke